Ken Fisher's CYTK Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 822,885 shares of Cytokinetics, Incorporated (CYTK) worth $52.29 M, representing 0.02% of the portfolio. First purchased in 2023-Q4, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Ken Fisher has maintained a strategic position in CYTK, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 176,966 shares. Largest reduction occurred in Q2 2025, reducing 59,778 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Cytokinetics Incorporated (CYTK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytokinetics Incorporated (CYTK) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +61,298 | Add 8.05% | 822,885 | $63.54 |
| Q3 2025 | +27,907 | Add 3.80% | 761,587 | $54.96 |
| Q2 2025 | -59,778 | Reduce 7.53% | 733,680 | $33.04 |
| Q1 2025 | +176,966 | Add 28.71% | 793,458 | $40.19 |
| Q4 2024 | +74,208 | Add 13.68% | 616,492 | $47.04 |
| Q3 2024 | +7,764 | Add 1.45% | 542,284 | $52.80 |
| Q2 2024 | -4,277 | Reduce 0.79% | 534,520 | $54.18 |
| Q1 2024 | +2,751 | Add 0.51% | 538,797 | $70.11 |
| Q4 2023 | +536,046 | New Buy | 536,046 | $83.49 |
Ken Fisher's Cytokinetics Incorporated Investment FAQs
Ken Fisher first purchased Cytokinetics, Incorporated (CYTK) in Q4 2023, acquiring 536,046 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Cytokinetics, Incorporated (CYTK) for 9 quarters since Q4 2023.
Ken Fisher's largest addition to Cytokinetics, Incorporated (CYTK) was in Q4 2023, adding 536,046 shares worth $44.75 M.
According to the latest 13F filing for Q4 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 822,885 shares of Cytokinetics, Incorporated (CYTK), valued at approximately $52.29 M.
As of the Q4 2025 filing, Cytokinetics, Incorporated (CYTK) represents approximately 0.02% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Cytokinetics, Incorporated (CYTK) was 822,885 shares, as reported at the end of Q4 2025.